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GWAS studies of autoimmune disorders have yielded hundreds of replicated associations,
but moving from genetic association to functional studies with potential clinical relevance is a
challenge. Leveraging GWAS data, Lee et al. now identify FOXO3 activity as predictive of disease
severity in Crohn’s disease and rheumatoid arthritis as well as malaria, likely by acting through
regulation of cytokine production in monocytes.The deluge of GWAS publications over
the last several years have provoked
concern that the generally very modest
effect sizes of the associations will be
difficult to translate into meaningful
insights into disease mechanisms, let
alone provide useful diagnostic markers.
Nevertheless, in the case of autoimmune
diseases, GWASs have been particularly
fruitful in terms of identifying large
numbers of reproducible associations
and have revealed intriguing overlaps
between different autoimmune disorders
that involve both the innate and adaptive
immune systems (Cho and Gregersen,
2011). While coding region variants with
defined effects on immune function have
been identified, manyGWASassociations
appear to involve regulatory functions that
can be tied to quantitative immune traits
(Gregersen et al., 2012). The report by
Lee et al. (2013) in this issue of Cell pro-
vides a beautiful integration of genetic,
clinical, and functional data in mouse
and human to shed light on the
pathway influenced by such a noncoding
SNP. The study also extends the applica-
tion of GWAS to encompass genetic
influences on disease outcome, indepen-
dent of the usual focus on disease
susceptibility.
The current report begins with a focus
on genes related to IL7 and IL2 signaling
pathways that were previously shown to
vary in expression patterns according to
disease prognosis in Crohn’s disease,
systemic lupus and vasculitis (McKinney
et al., 2010). By focusing on these path-
ways and limiting the analysis to 1,134SNPs in 81 genes, the authors mitigated
the requirement for stringent statistical
significance generally demanded for
GWAS studies; nevertheless they met
this standard (p < 53 108) by performing
replication studies. Several genes in the
IL7 and IL2 pathways are associated
with disease susceptibility, but none of
these influenced disease outcome. In
contrast, a strong correlation with disease
outcome was observed for the single-
nucleotide variant rs12212067, in the
FOXO3 locus, which has not been previ-
ously associatedwith risk for human auto-
immune disorders. FOXO3 is amember of
the FOXO family of transcription factors,
most of which are widely expressed
and regulate diverse cellular programs
including cell-cycle control, DNA repair,
and response to oxidative stress (Hedrick,
2009), with a potential impact on
longevity. FOXO3 in particular has also
been previously implicated in more
specialized immune regulatory functions
in macrophages (Litvak et al., 2012),
dendritic cells, and T cells (Dejean et al.,
2009). Thus it is not entirely surprising
that this gene might regulate the expres-
sion of human immune and inflammatory
disease phenotypes.
Using a local resource of genotyped
healthy controls, Lee et al. went on to
show that a haplotype containing the
minor allele (G) of rs12212067 was
associated with higher transcription of
FOXO3 in bloodmonocytes, but only after
stimulation with lipopolysaccharide (LPS).
Moreover, the minor (G) allele at FOXO3
downregulates the production of TNFCell 155, Sand several other proinflammatory cyto-
kines in response to LPS and other
toll-like receptor 4 (TLR) ligands. In
contrast, IL10, a cytokine that is associ-
ated with anti-inflammatory effects, is
upregulated by the minor allele in
response to TLR stimulation. These re-
sults are consistent with themore indolent
disease course that was observed in
Crohn’s disease patients who carry this
haplotype. FOXO3 is exported out of the
nucleus after cell activation, and, in a
further surprising twist to this story, a
more rapid time course of nuclear reaccu-
mulation of FOXO3 was associated with
the minor (G) allele. The time-dependent
effects of these events on cytokine pro-
duction were mediated by TGFb. Further
experiments suggested direct regula-
tion of TGFb by FOXO3 itself, although
other mechanisms may also account for
the TGFb dependent anti-inflammatory
effects on monocyte function.
It is important to emphasize that all of
these functional studies were carried out
in human cells by taking advantage of
the Cambridge Bioresource. This is an
invaluable collection of healthy volunteers
who can be recalled for functional studies
on the basis of their genotype, and this
resource supported some of the first
functional studies of GWAS associations
in autoimmunity (Dendrou et al., 2009).
Without this population resource, a
convincing connection between FOXO3
genotype and phenotype would be diffi-
cult to establish, because studies of
Crohn’s patients would be confounded
by disease activity and therapy, andeptember 26, 2013 ª2013 Elsevier Inc. 11
Figure 1. The Identification of FOXO3 as a Marker of Disease
Outcomes
An integrative analytic approach that utilizes data from GWAS and clinical
outcomes along with work in human monocytes and mouse models has
revealed that differences in FOXO3 levels alter the balance of proinflammatory
(TNF) versus anti-inflammatory (IL10) cytokine production. This influences the
outcome of various diseases that are either exacerbated or ameliorated by
these inflammatory responses.functional studies in cell lines
may not reflect the situation
in native cells. Lee et al. pro-
vide supporting data in
FOXO3-deficient mice, show-
ing more severe disease
activity in a colitis model, but
overall the most compelling
mechanistic data supporting
the human genetic findings
come from studies in native
human cells.
The identification of labora-
tory predictors of individual
variation in disease outcome
and response to therapy is
the holy grail of personalized
medicine. Progress has been
tangible in the area of
oncology, where the molecu-
lar taxonomy of the tumor is
prognostically informative
and is driving selection of
therapy (McCarthy et al.,
2013). In contrast, progress
has been slow in developing
useful biomarkers in autoim-
mune and inflammatory disor-
ders. Lee et al. provide
evidence for some prognostic
value for FOXO3 in progres-
sion and severity not only inCrohn’s disease but also for rheumatoid
arthritis and malaria. Satisfyingly, the
minor allele SNP was associated with a
less dire outcome in rheumatoid arthritis,
similar to Crohn’s, as would be predicted
for an autoimmune disease, whereas the
same variant was associated with a
more severe course of malaria infection
as might be predicted for an infectious
disease relying on cytokine-mediated
pathogen clearance. It will be of great
interest to whether the prognostic utility
of FOXO3 genotype can be confirmed in
larger studies. This may be correlated
with the TGFb dependent phenotypes in
monocytes defined by Lee et al. or with
other immune cell phenotypes. One of
the major barriers to these studies is the
absence of large cohorts with well-char-
acterized disease outcome as part of the
phenotype because most large collec-
tions have been assembled to address
the issue of disease susceptibility. For12 Cell 155, September 26, 2013 ª2013 Elseexample, studies of response to TNF
inhibition in rheumatoid arthritis have
been very disappointing in part because
of lack of high-quality, prospectively
collected data on disease activity and
progression. Failure may also be related
to the exclusively univariate approaches
to analysis. In this regard, a recent crowd
sourcing initiative to examine genetic pre-
dictors of drug response in RA may
generate more insights (Plenge et al.,
2013).
The incorporation of GWAS data into
the larger universe of basic biology,
network analysis, and clinical data is
an exciting, if daunting challenge. As out-
lined in Figure 1, the elucidation of the
specific functional effects of genetic vari-
ants discovered in GWAS depends on the
creative integration of information from
multiple sources, including the ability to
utilize human cells of defined genotype
as a complement to studies inmurine sys-vier Inc.tems. It is not unreasonable to
hope that this can lead to the
development of new diagnos-
tics and therapeutics that can
be tied to personalized infor-
mation about likely disease
outcomes. The report of Lee
et al. is a compelling example
of how the understanding of
human genetics and funda-
mental cell biology can be
brought to bear on an impor-
tant clinical problem, with the
implication that FOXO genes
may hold secrets not only
of a long life, but also of a
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